Conventional drug delivery systems face significant limitations including poor bioavailability, nonspecific distribution, systemic toxicity, and rapid clearance from circulation, which collectively diminish therapeutic efficacy and compromise patient safety. Nanomedicine has emerged as a transformative strategy to address these challenges by enabling precise drug targeting, controlled release kinetics, and enhanced therapeutic indices through rationally designed nanocarriers. This article examines the fundamental principles of nanomedicine-based targeted drug delivery, emphasizing critical aspects of nanoparticle design, targeting mechanisms, and controlled release strategies. We discuss the physicochemical properties that govern nanocarrier behavior, including size, surface chemistry, and architecture, as well as passive and active targeting approaches that exploit unique pathophysiological features of diseased tissues. The complex biological barriers encountered during systemic administration, such as protein corona formation, immune recognition, vascular extravasation, and intracellular trafficking, are analyzed in the context of rational nanocarrier optimization. Furthermore, we evaluate preclinical models and translational pathways, review clinical applications across oncology, infectious diseases, and inflammatory disorders, and assess therapeutic outcomes compared to conventional treatments. Safety profiles, toxicological considerations, and regulatory frameworks governing nanomedicine development are critically examined. Finally, we provide future perspectives on overcoming remaining translational challenges, advancing personalized nanomedicine, and achieving widespread clinical implementation. This comprehensive review underscores the profound impact of nanomedicine on modern therapeutics and its potential to revolutionize patient care through precision drug delivery.